

Not for disclosure, distribution or reproduction in the US,
Canada, Australia or Japan.

August 30, 2016

Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
tim.lange@evonik.com

Evonik announces issuance of bonds with a volume of up to €1.9 billion

- Three tranches with a minimum volume of €500 million each
- Proceeds of bonds will be used for the planned acquisition of the Specialty & Coating Additives business of Air Products

Essen. This morning Evonik Industries AG has announced to issue up to €1.9 billion of corporate bonds. The bonds will be issued by the subsidiary Evonik Finance B.V. Three tranches with maturities of 4.5, 8 and 12 years are marketed to investors. Proceeds will be used for the planned acquisition of the Specialty & Coating Additives business of Air Products. The acquisition price of approximately €3.5 billion (3.8 billion US dollars) will be paid via cash reserves of €1.6 billion as well as with the proceeds of the bonds.

Evonik Industries AG is rated Baa1 by Moody's as well as BBB+ by S&P both with stable outlook.

Joint active Bookrunners are Barclays, BNP PARIBAS, Deutsche Bank, HSBC, J.P. Morgan and SG CIB.

Further information:
www.evonik.de

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann, Deputy Chairman
Dr. Ralph Sven Kaufmann
Thomas Wessel
Ute Wolf

Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation of an offer to buy securities. In particular, this document constitutes neither an offer to sell nor a solicitation of an offer to purchase securities in the United States. The securities of Evonik Finance B.V. described above (the "Securities") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U. S. Securities Act of 1933, as amended (the "Securities Act")) absent registration or an exemption from registration under the Securities Act. The Securities have not been and will not be registered under the Securities Act or the securities laws of any State of the United States. There will be no public offering of the Securities in the United States.

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.